secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2026-08-13T20:05:58+00:00
Accession:  0001708599-26-000048
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina reports Q2 net loss of $8.9M, advances SER-252 trial ahead of schedule
-----------------------------------------------------------------------------

- Net loss attributable to common shareholders was $8.9M, or $(0.55) per share, vs $6.6M loss ($(0.66)) in Q2 2025.
- Operating expenses rose to $6.8M from $5.7M; R&D $3.8M, G&A $3.0M; cash $23.0M at June 30, 2026.
- Completed enrollment/dosing of all 8 patients in Cohort 1 of SER-252 Phase 1b registrational study in July 2026, ahead of Q3 2026 guidance.
- Top-line data from single-ascending-dose arm targeted for H1 2027; partnered with Gannet BioChem for process development and manufacturing.
- Appointed Farrell Simon, Pharm.D., to Board of Directors and Audit/Compensation Committees in July 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000170859926000048/0001708599-26-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000170859926000048/ser-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001708599-26-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer